Merck
1Q Revenues: $5.4 billion (+1%)
1Q Earnings: $1.5 billion (+11%)
Comments: Zocor and Singulair performed well in the quarter. Worldwide sales of Singulair were $801 million, up 9%. Worldwide Zocor sales were $1.1 billion, down 4%, but U.S. sales were up 13%. Strong results from partnerships drove earnings for the quarter. As reported by the Merck/Schering-Plough partnership, global sales of Zetia and Vytorin reached $793 million. Global sales by the Merck/Schering-Plough cholesterol partnership of Zetia reached $415 million in the quarter, up 25%. The company received FDA approval for Rotateq in the quarter. R&D expenses were $942 million for the quarter, up 11%.
Magazine
